Pre Clinical Study of Cr(III)-based Hypoglicemic Supplementin–Type 2 Diabetic Rats

Abstract

The chromium (III)-amino acid complex based hypoglicemic agent was investigated on pre-clinical study by the response of the blood glucoce level. This study was conducted on nicotinamide-streptozotocin induced diabetic Wistar rats. The rats were divided into 7 groups each consist of 4 animals. Three groups are control (+) with chromium picolinate (CrPic), control (-) diabetic group (DM) and control non diabetic (non DM). Furthermore, three groups were examined on the effect of Cr-AA [Cr(μ-OH)(glu)(OH)2]2·6H2O] (glu= glutamic) at dose (50, 150 and 300 μg/day). In addition, the last group was studied on the effect of control group by glibenclamide. The blood glucose levels were measured before and after treatment. The results show that supplementation of Cr(III)-complex in 8 weeks decreased the blood glucose level in range 46.446 – 79.593 %.